On November 17, 2015 Codiak BioSciences completed their series A funding round with $31 million in capital from Flagship Pioneering, ARCH Venture Partners, and Fidelity Management and Research Company.
On January 26, 2016 Codiak BioSciences completed their series B funding round with $61 million in capital from Flagship Pioneering (lead investor), ARCH Venture Partners (lead investor), Alexandria Venture, and Alaska Permanent Fund.
On November 27, 2017 Codiak BioSciences completed their series C funding round with $76.5 million in capital from Sirona Capital, Qatar Investment Authority, Flagship Pioneering, Fidelity Management and Research Company.
Codiak BioSciences Presents First Data on exoSTING - A Novel Engineered Exosome Therapeutic Targeting Checkpoint Refractory Tumors at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
Codiak BioSciences, Inc.
What You Need to Know About Codiak BioSciences
Xconomy: VCs Put More Dollars Into Exosomes as Codiak Bio Lands $76M